| Literature DB >> 26834824 |
Mengjie Wang1, Ling Tao2, Hongxi Xu1.
Abstract
Enterovirus 71 (EV71) is one of the causative agents of hand, foot, and mouth disease (HFMD), which sometimes leads to severe neurological disease and death in the Asia-Pacific region. In Chinese medicine, HFMD is caused mainly by an accumulation of damp-heat and toxicity in the body. No effective drugs are currently available for the treatment and prevention of EV71 infection. This review summarizes the potential Chinese herbal extracts and isolated compounds with antiviral activity against EV71 and their clinical applications, especially those categorized as heat-clearing and detoxifying.Entities:
Year: 2016 PMID: 26834824 PMCID: PMC4731985 DOI: 10.1186/s13020-016-0074-0
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 5.455
Anti-EV71 effects of extracts from Chinese medicines
| Category | Plant source and reference | Fraction | Anti-EV71 effect | Mechanism |
|---|---|---|---|---|
|
|
| Water extract | Reduces CPE (EC50 125.92 μg/mL, SI 101.65), virus titre, plaque formation (EC50 8.9–20.6 μg/mL, SI above 48), viral RNA production and 3A protein expression, inhibits EV71-induced apoptosis, prevents IκBα degradation, and down-regulates IL-6 | Inhibits viral replication, and proinflammatory response |
|
| 95 % ethanol extract | Reduces CPE and plaque formation (EC50 78.46–125.00 μg/mL, SI 5.96-9.49), raises IL-6 level | Destroys virus | |
|
| Water extract | Reduces CPE and plaque formation (EC50 35.88 μg/mL, SI above 27), and virus yield, inhibits EV71-induced apoptosis, viral 2A protease activity, expression of IL-6 and RANTES, and reduces the viral load in intestine of suckling mice | Inhibits viral protease activity, viral RNA replication, and influences host cell factors | |
|
| Ethyl acetate extract | Reduces CPE (EC50 4.21 μg/mL, SI above 97) and plaque formation | Inhibits virus binding | |
|
| Water extract | Reduces CPE (EC50 8.9 μg/mL) and virus titre | Inhibits activation of MEK1-ERK signalling pathway | |
|
| Methanol extract | Reduces CPE (EC50 65 μg/mL) | Inhibits viral RNA replication | |
|
| Ethyl acetate, and butanol extracts | Reduces CPE | ||
| Other Chinese medicine |
| Water extract | Reduces CPE (EC50 0.742 mg/mL for SA1, 0.585 mg/mL for SA2), plaque formation, viral yield, and EV71-induced apoptosis | Inhibits viral RNA synthesis |
|
| Water extract | Reduces CPE (EC50 0.028 μg/mL, SI 107,000), and decreases IFN production | Inhibits viral attachment and penetration | |
|
| Water extract | Reduces CPE (EC50 0.056 μg/mL, SI 5000) | Prevents viral attachment and penetration | |
|
| Acetone extract | Reduces CPE and plaque formation (EC50 26.11 μg/mL, SI 5.56), and down-regulated IL-6, IL-1β, IL-8 levels | Prevents viral infection, inactivated virus, and inhibited viral replication | |
|
| Water extract | Reduces CPE (EC50 0.163–0.824 mg/mL, SI 1.752–8.859), virus yield, virus titre | Inhibits viral attachment and penetration | |
| Chinese medicinal formulae |
| Water extract | Reduces CPE (EC50 0.21 μg/mL, SI above 23809.52) | Inhibits viral attachment and penetration |
|
| Water extract precipitated with ethanol | Reduces CPE (EC50 below 31.2 μg/mL) | Inhibits viral adsorption |
Anti-EV71 effects of pure compounds from Chinese medicines
| Category | Compound and reference | Chemical structure | Plant source | Chemical class | Anti-EV71 effect | Mechanism |
|---|---|---|---|---|---|---|
| Flavones | Apigenin [ |
|
| Flavone | Reduces CPE (EC50 25.5 μM, SI 8.7), viral protein expression, ROS generation, cytokine up-regulation | Interferes with viral IRES activity, JNK activation, association of EV71 RNA with hnRNP A1 and A2 proteins |
| Chrysosplenetin [ |
|
| Flavonol | Reduces CPE (EC50, 0.17 μM, SI 107.5), plaque formation, production of viral VP1 protein, and the viral yield | Shows strong antiviral potency targeting the post-attachment stage | |
| Penduletin [ |
|
| Flavonol | Reduces CPE (EC50 0.17 μM, SI 655.5), plaque formation, production of viral VP1 protein, and the viral yield | Shows strong antiviral potency targeting the post-attachment stage | |
| 7,8-dihydroxyflavone [ |
|
| Flavone | Shows 20 % cytotoxicity, 80 % CPE reduction and 40 % IRES activity at 50 μM | ||
| Kaempferol [ |
|
| Flavonol | Shows 20 % cytotoxicity, 80 % CPE reduction and 40 % IRES activity at 50 μM, reduces virus yield, and viral protein expression | Changes the expression level of FUBP1, FUBP3, HNRPD, HNRH1 and HNRPF proteins, which may contribute to the anti-EV71 activity | |
| Quercetin [ |
|
| Flavonol | Shows 20 % cytotoxicity, 80 % CPE reduction and 40 % IRES activity at 50 μM | ||
| Hesperetin [ |
|
| Flavonone | Shows 20 % cytotoxicity, 80 % CPE reduction and 40 % IRES activity at 50 μM | ||
| Hesperidin [ |
|
| Flavonone glucoside | Shows 20 % cytotoxicity, 80 % CPE reduction at 50 μM | ||
| Eupafolin [ |
|
| Flavone | Reduces CPE (EC50 0.44 μM, SI 808), plaque formation, decreases virus-induced IL-6 and RANTES expression, and decreases the phosphorylation of cytokine induction-related proteins | Inactivates the virus, and suppresses proinflammatory cytokines | |
| Chrysin [ |
|
| Flavone | Reduces CPE (EC50 10 μM, SI 20), viral RNA, capsid protein, and infectious virions | Inhibits viral 3C protease | |
| Chrysin phosphate ester [ |
| Synthesised | Flavone derivative | Reduces CPE (EC50 6 μM, SI 33), viral RNA, capsid protein, and infectious virion | Inhibits viral 3C protease | |
| Luteolin [ |
|
| Flavone | Reduces CPE (EC50 31.56 μM, SI 9.25 in RD cells), inhibits viral RNA replication | Targets post-attachment stage | |
| Rutin [ |
|
| Flavonoid glycoside | Reduces CPE (200 μM), viral RNA level, and virus titre | Inhibits activation of MEK1-ERK signalling pathway | |
| Formononetin [ |
|
| Isoflavone | Reduces CPE (EC50 3.98 μM, SI 43.07), viral RNA replication, protein synthesis | Suppresses ERK, p38, and JNK activation, and COX-2/PGE2 expression | |
| Terpenes | Ursolic acid [ |
|
| Triterpenoid | Reduces CPE (EC50 1.1 μM, SI 200) | Inhibits viral infection and replication process |
| Linalool [ |
|
| Monoterpene | Reduces CPE (EC50 273.60 μM, SI 4.2) | ||
| Raoulic acid [ |
|
| Diterpene | Reduces CPE (EC50 0.25 μM, SI above 658) | ||
| Glycyrrhizic acid [ |
|
| Triterpenoid | Reduces plaque formation at 3, 5 μM and virus titre and expression of viral VP1 protein | Targets post-viral entry process | |
| Geniposide [ |
|
| Monoterpene | Reduces CPE, viral RNA level, plaque formation, and inhibited viral IRES activity | ||
| GLTA [ |
|
| Triterpenoid | Reduces CPE (EC50 below 0.16 μg/mL) | Blocks adsorption and uncoating | |
| GLTB [ |
|
| Triterpenoid | Reduces CPE (EC50 below 0.16 μg/mL) | Blocks adsorption and uncoating | |
| Hederasaponin B [ |
|
| Triterpenoid | Reduces CPE (EC50 24.77 μM, SI 2.02) and viral capsid protein expression | Inhibits viral capsid protein expression | |
| Ginsenoside Rg2 [ |
|
| Triterpenoid | Reduces CPE | ||
| Polyphenols | Epigallocatechin gallate (EGCG) [ |
|
| Polyphenol | Reduces plaque formation, viral RNA level, and raises the survival rate of Vero cells approximately fourfold relative to untreated infected cells at 25 μM | Has antioxidant activity, and suppresses viral RNA replication |
| Gallocatechin gallate (GCG) [ |
|
| Polyphenol | Reduces plaque formation, and raises the survival rate approximately fourfold higher than the infected group at 25 μM | ||
| Geraniin [ |
|
| Tannin | Reduces CPE, viral yield, can improve survival and clinical score in infected mice (EC50 10.5 μM, SI 20) | ||
| Chebulagic acid [ |
|
| Tannin | Reduces CPE, and reduces the mortality of infected mice, relieves the symptoms (EC50 13.1 μM, SI 16) | Inhibits viral replication | |
| Corilagin [ |
|
| Ellagitannins | Reduces CPE (EC50 5.6 μg/mL) | ||
| Punicalagin [ |
|
| Tannin | Reduces CPE (EC50 15 μg/mL), viral RNA level, and mice mortality in vivo | ||
| Steroids | Timosaponin B-II [ |
|
| Steroidal saponin | Reduces CPE (EC50 4.3 μM, SI 92.9) | |
| Anemarrhenasaponin II [ |
|
| Steroidal saponin | Reduces CPE (EC50 22.2 μM, SI 3.8) | ||
| Timosaponin G [ |
|
| Steroidal saponin | Reduces CPE (EC50 9.1 μM, SI 2.3) | ||
| Timosaponin A-IV [ |
|
| Steroidal saponin | Reduces CPE (EC50 4.7 μM, SI 2.2) | ||
| Timosaponin A-III [ |
|
| Steroidal saponin | Reduces CPE (EC50 1.1 μM, SI 2.4) | ||
| Shatavarin IV [ |
|
| Steroidal saponin | Reduces CPE (EC50 2.2 μM, SI 1.8) | ||
| Miscellaneous | Gallic acid [ |
|
| Phenolic acid | Reduces CPE (EC50 4.47 μM, SI 99.57) | Has antioxidant activity |
| Resveratrol [ |
|
| Phenol | Reduces CPE (EC50 20.2 mM, SI 15.2) | Blocks IKKs/NF-κB signalling pathway | |
| Allophycocyanin [ |
| Protein | Reduces CPE (EC50 0.045 μM, SI 36.7), plaque formation (EC50 0.056 μM, SI 29.5), delays viral RNA synthesis, and inhibits EV71-induced apoptosis | Interferes with early stage of viral replication | ||
| Caffeic acid [ |
|
| Phenol | Reduces CPE (EC50 23.87 μM, SI 11.51), plaque formation | ||
| Aloe-emodin [ |
|
| Anthraquinone | Induces IFN expression, activates NO production, and reduces plaque formation (EC50 0.5-1.9 μM, SI above 5540) | Activates type I and II IFN signalling pathways against viral replication | |
| Garlicin [ |
|
| Diallyl disulfide | Reduces CPE (EC50 99.95 μM, SI 44.66) | ||
| Oblongifolin J [ |
|
| Prenylated benzoylphloroglucinol | Reduces CPE (EC50 31.1 μM, SI 1.5) | ||
| Oblongifolin M [ |
|
| Prenylated benzoylphloroglucinol | Reduces CPE (EC50 16.1 μM, SI 2.4) | ||
| Euxanthone [ |
|
| Xanthone | Reduces CPE (EC50 12.2 μM, SI 3.0) | ||
| Gramine derivative 4 s [ |
| Synthesised | Indole alkaloid | Reduces CPE (EC50 9.1 μM, SI 14.3), viral RNA replication, protein synthesis, and virus-induced apoptosis | Inhibits viral adsorption or affects viral release from the cells | |
| Chlorogenic acid [ |
|
| Aromatic acids | Reduces plaque formation (EC50 6.3 μg/mL) | Inhibits EV71 2A transcription and translation | |
| Magnesium lithospermate B [ |
|
| Aromatic acids | Reduces CPE (EC50 0.09 mM, SI 10.52), plaque formation, protein expression | Influences virus infection, and IRES activity | |
| Rosmarinic acid [ |
|
| Aromatic acids | Reduces CPE (EC50 0.50 mM, SI 2.97), plaque formation, protein expression | Influences virus infection, and IRES activity | |
| Matrine [ |
|
| Gordon landmines ketoneses alkaloid | Reduces viral RNA level, and mice mortality in vivo | ||
| Lycorine [ |
|
| Benzylphenethylamine alkaloid | Reduces CPE (EC50 0.48 μg/mL, SI above 100), viral RNA level, and mice mortality in vivo | Influences viral protein expression |
Chinese medicines recommended for the treatment of HMFD by the Chinese government
| Classification of HMFD | CM syndrome | Chinese medicine | Composition |
|---|---|---|---|
| General |
|
|
|
|
|
| ||
|
| Forsythia suspense ( | ||
|
|
| ||
|
| Indigowoad root ( | ||
| Stagnation and steaming of |
|
| |
|
| Lodestone ( | ||
|
|
| ||
|
| Andrographolide sulfonate | ||
|
|
| ||
| Severe |
|
|
|
|
| Calculus bovis ( | ||
|
| See above | ||
|
| See above | ||
|
|
| ||
|
| See above | ||
| Urgent | Fading in |
|
|
|
|
| ||
|
|
| ||
| Recovering | Insufficient |
|
|
| Surgical | Oropharyngeal ulcer |
| Borneol ( |
|
| Pearl ( | ||
|
| Borneol ( |
Fig. 1Mechanisms of anti-EV71 components. Mechanisms of anti-EV71 activities associated with the shown CM-derived extracts and molecules were classified into six categories
Fig. 2Schematic diagram of the strategies used to assess anti-EV71 activities of Chinese herbal medicines. Shown are different methods that are used to screen for anti-EV71 activity in fractions and compounds from Chinese herbal medicines. The anti-EV71 mechanisms target different points in the EV71 life cycle